MDT

86.1

+0.48%↑

A

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

A

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

A

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

A

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

A

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

Search

Simulations Plus Inc

Abierto

SectorSanidad

12.07 4.87

Resumen

Variación precio

24h

Actual

Mínimo

11.29

Máximo

12.08

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+67.25% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.45%

Próximas Ganancias

9 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-139M

229M

Apertura anterior

7.2

Cierre anterior

12.07

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

148 / 349 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 mar 2026, 23:31 UTC

Acciones populares

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Ganancias

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 abr 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Adquisiciones, fusiones, absorciones

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Ganancias

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Charlas de Mercado
Ganancias

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Charlas de Mercado

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Adquisiciones, fusiones, absorciones

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Charlas de Mercado

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Ganancias

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Ganancias

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Ganancias

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Ganancias

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Ganancias

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Ganancias

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Ganancias

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Ganancias

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Charlas de Mercado
Ganancias

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Ganancias

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Ganancias

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Ganancias

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Ganancias

Nike CEO: Converse Remains Important to Portfolio

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

67.25% repunte

Estimación a 12 Meses

Media 19 USD  67.25%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

148 / 349 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat